Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierCHU de Bordeaux Pellegrin [Bordeaux]
dc.contributor.authorNGUYEN, Joanne Thanh-Tâm
hal.structure.identifierCHU de Bordeaux Pellegrin [Bordeaux]
dc.contributor.authorFERRIÈRE, Amandine
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorTABARIN, Antoine
dc.date.accessioned2025-05-27T08:48:31Z
dc.date.available2025-05-27T08:48:31Z
dc.date.issued2024-02-08
dc.identifier.issn1664-2392en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206740
dc.description.abstractEnThis report describes a rare case of a 20-year-old man with an ACTH- and prolactin-secreting invasive pituitary macroadenoma causing hyperprolactinemia and Cushing’s disease. He was later found to have an AIP mutation. Treatment with cabergoline (1.5 mg weekly) normalized prolactin concentrations and induced a major shrinkage of the adenoma. Not only was urinary free cortisol normalized for more than 14 years, but also the treatment induced normal hypothalamo-pituitary-adrenal (HPA) axis function as illustrated by the reappearance of a normal cortisol/ACTH circadian rhythm, cortisol suppression to dexamethasone, and disappearance of the excessive and aberrant responses to CRH and desmopressin, respectively. This case is the first description of complete restoration of the physiological characteristics of the HPA axis by a medication during the treatment of Cushing’s disease. Although exceptional, it illustrates that drugs targeting the pituitary adenoma can bring true complete remission of Cushing’s disease. Copyright © 2024 Nguyen, Ferrière and Tabarin.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enCabergoline
dc.subject.enPituitary macroadenoma
dc.subject.enProlactinoma
dc.subject.enRemission
dc.subject.enAIP mutation
dc.subject.enCushing’s disease
dc.title.enCase report: Complete restoration of the HPA axis function in Cushing’s disease with drug treatment
dc.title.alternativeFront Endocrinolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fendo.2024.1337741en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed38390203en_US
bordeaux.journalFrontiers in Endocrinologyen_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPhysiopathologie de l'équilibre énergétique et obésitéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05086307
hal.version1
hal.date.transferred2025-05-27T08:48:33Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Endocrinology&rft.date=2024-02-08&rft.volume=15&rft.eissn=1664-2392&rft.issn=1664-2392&rft.au=NGUYEN,%20Joanne%20Thanh-T%C3%A2m&FERRI%C3%88RE,%20Amandine&TABARIN,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée